文献速递慢性肾脏病肾小球疾病

非酒精性脂肪性肝病在糖尿病患者肾功能演变中的作用

Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究为回顾性观察研究,纳入102例2型糖尿病患者,按NAFLD评分分组,随访约75.8个月。结果显示NAFLD评分最高组基线eGFR更低、蛋白尿更高,随访期间eGFR下降更显著,CKD进展风险显著增高(OR 7.50,95%CI 2.76-20.35,P≤0.001)。

要点

  • NAFLD高危纤维化组CKD进展风险显著增高(OR 7.50)。
  • 该组基线eGFR更低、蛋白尿更高。
  • 建议将NAFLD作为T2DM患者CKD进展的风险因素评估。

核心结论

  • 合并高危纤维化NAFLD的T2DM患者CKD进展风险更高。

研究设计与样本

  • 回顾性观察研究,纳入102例eGFR>30 mL/min/1.73 m2的T2DM患者。
  • NAFLD依据超声和/或NAFLD评分定义的纤维化,按评分分三组。

主要发现

  • Group 3基线eGFR较低(84.8±40.4 vs 71.4±30.6 mL/min/1.73 m2,P=0.03),蛋白尿较高(0.56±0.77 vs 1.59±2.70 g/24 h,P=0.05)。
  • 随访75.8±23.9个月后,Group 3的eGFR显著下降(66.6±33.3 vs 36.8±23.1 mL/min/1.73 m2,P≤0.01)。
  • Group 3的CKD进展风险(eGFR下降>50%)OR为7.50(95%CI 2.76-20.35,P≤0.001)。

关键数值与推荐

  • NAFLD评分分组:Group 1 <-1.85;Group 2 -1.85至0.18;Group 3 >0.18。
  • CKD进展定义为eGFR下降>50%。

临床怎么用

  • 对T2DM患者应评估NAFLD及其纤维化风险,以优化治疗。

局限性

  • 回顾性观察设计,样本量较小(102例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing prevalence of type 2 diabetes mellitus (T2DM) has influenced in an increasing prevalence of chronic kidney disease (CKD). Little is known about the influence of non-alcoholic fatty liver disease (NAFLD) on the progression of CKD. The aim of this study was to analyse the role of NAFLD and its severity in the progression of renal function in patients with T2DM. METHODS: We conducted a retrospective and observational study including patients with T2DM and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2. NAFLD was defined as the presence of compatible ultrasonography and/or the presence of fibrosis using the NAFLD score. Patients were classified into three groups according to the NAFLD score: Group 1: <-1.85; Group 2: -1.85-0.18 and Group 3: >0.18. RESULTS: A total of 102 patients were included [67.6% males, median age 59 years [interquartile range (IQR) 53-64)], with a median time of T2DM evolution of 70 months (IQR 39-131). Group 3 had lower eGFR (84.8 ± 40.4 versus 71.4 ± 30.6 mL/min/1.73 m2; P = 0.03) and higher proteinuria at baseline (0.56 ± 0.77 versus 1.59 ± 2.70 g/24 h; P = 0.05). After a follow-up time of 75.8 ± 23.9 months, Group 3 had a significant decrease in eGFR (66.6 ± 33.3 versus 36.8 ± 23.1 mL/min/1.73 m2; P ≤ 0.01) and a higher risk of CKD progression [odds ratio 7.50 (95% confidence interval 2.76-20.35); P ≤ 0.001] defined as a decrease in eGFR of >50%. CONCLUSIONS: The presence of NAFLD with high-risk fibrosis confers higher risk of CKD progression in patients with T2DM. Therefore NAFLD should be a risk factor evaluated in these patients to optimize treatment.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Aubert L, Sandino J, Gutiérrez-Solís E, et al. Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. Nephrol Dial Transplant. 2022. PMID: 33983444. doi:10.1093/ndt/gfab176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。